Anzeige
Mehr »
Donnerstag, 23.10.2025 - Börsentäglich über 12.000 News
Das Comeback des Goldrauschs - diesmal ausgelöst durch eine Währungskrise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PHG6 | ISIN: CA59935V1076 | Ticker-Symbol:
NASDAQ
23.10.25 | 22:00
1,890 US-Dollar
-1,56 % -0,030
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
MILESTONE PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
MILESTONE PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur MILESTONE PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.10.Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 20253
11.09.Wells Fargo initiates Milestone Pharmaceuticals stock with Overweight rating16
12.08.Milestone Pharmaceuticals GAAP EPS of -$0.20 misses by $0.023
12.08.Milestone Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans1
12.08.Milestone Pharmaceuticals Inc. - 8-K, Current Report1
12.08.Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update351FDA Accepted the Company's Response to the CRL for CARDAMYST (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST...
► Artikel lesen
12.08.Milestone Pharmaceuticals Inc. - 10-Q, Quarterly Report1
11.07.Milestone Pharmaceuticals Launches Public Offering To Support Etripamil Development5
MILESTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln
11.07.Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge3
11.07.Why Is Milestone Pharmaceuticals Stock Plunging On Friday?1
11.07.Milestone Pharmaceuticals plunges after pricing $52.5M offering3
11.07.Milestone Pharmaceuticals prices $52.5 million public offering2
11.07.Milestone Pharmaceuticals stock plunges on public offering announcement4
11.07.Kapitalerhöhung angekündigt: Aktie von Milestone Pharmaceuticals bricht ein3
11.07.Milestone Pharmaceuticals proposes capital raise via securities offering1
11.07.Milestone Pharmaceuticals announces public offering of shares and warrants3
11.07.Milestone Pharmaceuticals Inc. - 8-K, Current Report1
11.07.Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST (etripamil) Nasal Spray400New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone®...
► Artikel lesen
17.06.Milestone Pharmaceuticals resubmits Cardamyst filing after FDA response8
16.06.Milestone Pharma Announces Submission Of Its Response To CRL Regarding NDA For CARDAMYST1
Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1